Keyphrases
ABCG2
31%
Adipokinetic Hormone
6%
Adipose-derived Stem Cells
6%
Advanced Stage
6%
Adverse Effects
6%
Biodistribution
31%
Bioluminescence Imaging
62%
Cancer Relapse
12%
Cancer Stem-like
31%
Cell Clones
31%
Cell-based
100%
CES2
31%
Chemotherapy
31%
Cisplatin
31%
Complete Tumor Response
6%
Corrective Measures
31%
Debulking Surgery
31%
Disease Stage
6%
Drug Efflux Pump
6%
Drug Resistance
31%
Enzyme Activity
31%
Enzyme Treatment
100%
Genetic Engineering
31%
Gynecologic Malignancies
6%
Healthy Tissue
31%
Hematology
31%
High Mortality Rate
31%
Human Ovarian Cancer Cell
6%
Imaging Magnetic Resonance
31%
Immunodeficient Mice
31%
Immunohistochemistry
37%
Intraperitoneal Tumor
31%
Irinotecan
31%
Long-term Survival
37%
Low Dose Rate
31%
Magnetic Resonance Imaging
62%
Metastasis
31%
Metastatic Disease
37%
Metastatic Ovarian Cancer
31%
Multidrug Resistance Protein 1 (MDR1)
31%
Multidrug-resistant
93%
Nanoluciferase
31%
Necrotic Lesion
31%
Non-surgical
31%
Optimal Cytoreduction
31%
Ovarian Cancer
31%
Ovarian Cancer Cells
31%
Ovarian Tumor
6%
Overexpressing
62%
Paclitaxel
31%
Platinum Drugs
31%
Primary Ovarian Cancer
31%
Prodrug
31%
Published Data
31%
Recurrent Metastatic
6%
Recurrent Ovarian Cancer
100%
Recurrent Patients
31%
Resection
31%
Resistant Disease
31%
Response to Therapy
62%
Standard of Care
62%
Statistical Analysis
31%
Survival Benefit
68%
Survival Rate
37%
Targeted Therapy
31%
Therapeutic Potential
31%
Treatment Modalities
31%
Tumor Burden
31%
Tumor Response
56%
Tumor Stroma
6%
Tumor Survival
62%
Tumor Tissue
31%
Tumor Tropism
31%
United States
31%
Working Diagnosis
31%
Medicine and Dentistry
Adipose Derived Stem Cell
8%
Adipose Tissue
24%
Biodistribution
16%
Bioluminescence
33%
Breast Cancer Resistance Protein
16%
Cancer Cell
20%
Cancer Recurrence
8%
Carboxylesterase
16%
Cisplatin
16%
Cytoreductive Surgery
16%
Debulking Surgery
16%
Diseases
33%
Drug Resistance
16%
Enzyme Activity
16%
Enzyme Prodrug Therapy
100%
Fibrinogen
16%
Hematology
16%
Histopathology
16%
Immunohistochemistry
20%
Irinotecan
16%
Long Term Survival
20%
Magnetic Resonance Imaging
33%
Malignant Neoplasm
33%
Metastatic Carcinoma
37%
Mortality Rate
16%
Neoplasm
100%
Ovarian Cancer
66%
Paclitaxel
16%
Prodrug
16%
Recurrent Ovarian Cancer
100%
Stem Cell
100%
Surgery
16%
Survival Rate
20%
Targeted Therapy
16%